

1 **Adult onset asthma and interaction between genes and active tobacco smoking:**
2 **the GABRIEL consortium.**

3

4 J.M. Vonk^{1,2¶*}, S. Scholtens^{1¶}, D.S. Postma^{2,3}, M.F. Moffatt⁴, D. Jarvis^{5,6}, A. Ramasamy⁵, M. Wjst^{7,8}
5 E.R. Omenaas⁹, E. Bouzigon^{10,11}, F. Demenais^{10,11}, R. Nadif^{12,13}, V. Siroux^{14,15,16}, A.V. Polonikov¹⁷, M.
6 Solodilova¹⁷, V.P. Ivanov¹⁷, I. Curjurić^{18,19}, M. Imboden^{18,19}, A. Kumar^{18,19,20}, N. Probst-Hensch^{18,19}, L.
7 M. Ogorodova²¹, V.P. Puzyrev^{21,22}, E. Yu Bragina²², M.B. Freidin²², I.M. Nolte¹, A.M. Farrall²⁰,
8 W.O.C.M. Cookson⁴, D.P. Strachan²³, G.H. Koppelman^{2,24}, H. M. Boezen^{1,2}

9

10 ¹ University of Groningen, University Medical Center Groningen, Department of Epidemiology,
11 Groningen, the Netherlands.

12 ² University of Groningen, University Medical Center Groningen, Groningen Research Institute for
13 Asthma and COPD (GRIAC), Groningen, the Netherlands.

14 ³ University of Groningen, University Medical Center Groningen, Department of Pulmonology,
15 Groningen, the Netherlands.

16 ⁴ Division of Respiratory Sciences, Imperial College, London, United Kingdom

17 ⁵ Population Health and Occupational Disease, Imperial College, London, United Kingdom

18 ⁶ MRC-PHE Centre for Environment and Health, Imperial College, London, United Kingdom

19 ⁷ Institute of Medical Statistics and Epidemiology (IMSE), Klinikum Rechts der Isar, Technical
20 University, Munich, Germany

21 ⁸ Comprehensive Pneumology Center (CPC), Institute of Lung Biology and Disease (iLBD), Helmholtz
22 Center Munich, Neuherberg, Germany

23 ⁹ Centre for Clinical Research, Haukeland University Hospital, Bergen, Norway

24 ¹⁰ Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, F-75007, Paris,
25 France

26 ¹¹ INSERM, UMR-946, F-75010, Paris, France

27 ¹² INSERM, U1168, VIMA: Aging and chronic diseases. Epidemiological and public health
28 approaches, F-94807, Villejuif, France

29 ¹³ Univ Versailles St-Quentin-en-Yvelines, UMR-S 1168, F-78180, Montigny le Bretonneux, France

30 ¹⁴ INSERM, IAB, Team of Environmental Epidemiology applied to Reproduction and Respiratory
31 Health, F-38000 Grenoble, France.

32 ¹⁵ Univ. Grenoble Alpes, IAB, Team of Environmental Epidemiology applied to Reproduction and
33 Respiratory Health, F-38000 Grenoble, France.

34 ¹⁶ CHU de Grenoble, IAB, Team of Environmental Epidemiology applied to Reproduction and
35 Respiratory Health, F-38000 Grenoble, France.

36 ¹⁷ Kursk State Medical University, Department of Biology, Medical Genetics and Ecology, Kursk,
37 Russian Federation.

38 ¹⁸ Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel,
39 Switzerland.

40 ¹⁹ University of Basel, Basel, Switzerland.

41 ²⁰ Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom.

42 ²¹ Siberian State Medical University, Tomsk, Russia.

43 ²² Research Institute of Medical Genetics, Tomsk NPMC, Russia.

44 ²³ Population Health Research Institute, St George's, University of London, London, United Kingdom.

45 ²⁴ University of Groningen, University Medical Center Groningen, Department of Pediatric
46 Pulmonology and Pediatric Allergology, Beatrix Children's Hospital, Groningen, the Netherlands.

47

48

49 * Corresponding author

50 E-mail: j.m.vonk@umcg.nl (JMV)

51

52 [†]These authors contributed equally to this work

53 **Abstract**

54

55 **Background**

56 Genome-wide association studies have identified novel genetic associations for asthma, but without
57 taking into account the role of active tobacco smoking. This study aimed to identify novel genes that
58 interact with ever active tobacco smoking in adult onset asthma.

59

60 **Methods**

61 We performed a genome-wide interaction analysis in six studies participating in the GABRIEL
62 consortium following two meta-analyses approaches based on 1) the overall interaction effect and 2)
63 the genetic effect in subjects with and without smoking exposure. We performed a discovery meta-
64 analysis including 4,057 subjects of European descent and replicated our findings in an independent
65 cohort (LifeLines Cohort Study), including 12,475 subjects.

66

67 **Results**

68 First approach: 50 SNPs were selected based on an overall interaction effect at $p < 10^{-4}$. The most
69 pronounced interaction effect was observed for rs9969775 on chromosome 9 (discovery meta-
70 analysis: $OR_{int}=0.50$, $p=7.63 \cdot 10^{-5}$, replication: $OR_{int}=0.65$, $p=0.02$). Second approach: 35 SNPs were
71 selected based on the overall genetic effect in exposed subjects ($p < 10^{-4}$). The most pronounced
72 genetic effect was observed for rs5011804 on chromosome 12 (discovery meta-analysis $OR_{int}=1.50$,
73 $p=1.21 \cdot 10^{-4}$; replication: $OR_{int}=1.40$, $p=0.03$).

74

75 **Conclusions**

76 Using two genome-wide interaction approaches, we identified novel polymorphisms in non-annotated
77 intergenic regions on chromosomes 9 and 12, that showed suggestive evidence for interaction with
78 active tobacco smoking in the onset of adult asthma.

79

80 Introduction

81

82 Exposure to environmental tobacco smoke increases the risk to develop asthma in childhood [1].
83 However, the role of active tobacco smoking in the onset of adult asthma remains inconclusive.
84 Current and former smokers have a lower lung function [2-4] and increased bronchial
85 hyperresponsiveness [5], whereas active smoking increases asthma severity [6]. The evidence for
86 new onset asthma after active tobacco smoking is less clear. Active tobacco smoking has been
87 associated with the onset of adult asthma [7,8], but not in all studies [6,9,10]. It has been hypothesized
88 that tobacco smoking moderates the immune system by increasing IgE levels, thereby contributing to
89 asthma onset [11].

90 Asthma is a complex disease that is thought to be caused by an interaction of environmental
91 exposures and genetic susceptibility. Active tobacco smoking may increase the risk for asthma in a
92 susceptible population only. Two candidate gene studies have suggested an interaction between
93 active tobacco smoking and genetic variants in the occurrence of asthma in adults, i.e. the genes
94 thymic stromal lymphopoietin (*TSLP*) [12] and filaggrin (*FLG*) [13]. Similarly, a study showed an
95 interaction between active tobacco smoking and genes involved in lung function decline [14]. Above
96 studies were based on hypothesis driven gene selection. One genome-wide association study on adult
97 onset asthma, with a hypothesis free design, revealed that polymorphisms in the *HLA-DQ* gene
98 increase the risk for adult onset asthma [15], an effect that was independent of tobacco smoke
99 exposure.

100 Insight in the interaction between active tobacco smoking and genetic susceptibility is crucial for
101 further development on knowledge on the etiology of adult onset asthma and for the development of
102 effective strategies for asthma prevention. We therefore performed a genome-wide interaction (GWI)
103 analysis using data of studies participating in the GABRIEL consortium [15] We replicated our top hits
104 in a large population study in the Northern part of the Netherlands: LifeLines Cohort Study [16]. We set
105 out to identify new genetic variants that interact with active tobacco smoking with respect to asthma
106 onset at adult age.

107

108 **Methods**

109

110 **Subjects**

111 Data from six individual studies selected on presence of adult onset asthma data were included in the
112 discovery meta-analysis on the interaction between single nucleotide polymorphisms (SNPs) and ever
113 active tobacco smoking (Fig 1, S1 Checklist, S2 Checklist). All cases and controls were of European
114 descent and two studies had a family structure. The study was approved by the local Medical Ethical
115 Review Committees and all subjects gave written informed consent (Description of studies and ethical
116 approval in the supporting information (S1 File)). Adult onset asthma was defined as asthma
117 diagnosed by a doctor when the subject was 16 years of age or older, as defined within the GABRIEL
118 consortium [15]. Controls were all free of asthma, including childhood onset asthma. Active tobacco
119 smoking was defined as 'ever active tobacco smoking'. Details on the outcome and exposure
120 definition for the individual studies can be found in the S1 File.

121

122 **Fig 1. PRISMA Flow Diagram**

123

124 **Genotyping and quality control**

125 Genotyping was performed using the Illumina Human610 quad array (www.illumina.com) at CEA-
126 Centre National de Génomique, Evry, France. Details on the genotyping method have been described
127 previously [15]. We restricted our meta-analyses to SNPs fulfilling the following quality control criteria
128 in each study: genotype missing rate <3% in cases and controls, minor allele frequency >5% in
129 controls and consistency with Hardy-Weinberg equilibrium in controls ($p\text{-value} > 10^{-4}$). Samples with
130 >95% genotyping success rate were included in the analyses. We excluded putative non-European
131 samples, identified using EIGENSTRAT2.0 software.

132

133 **Statistical analyses**

134 All individual studies were analysed using a logistic regression model with adult onset asthma as
135 outcome. For each individual study a genome wide analysis on adult onset asthma was performed

136 using logistic regression analysis including the SNP, ever active tobacco smoking, as well as the
137 interaction between the SNP and ever active tobacco smoking to assess whether the effect of
138 smoking on adult asthma differed between subjects with different genotypes. Also a stratified analysis
139 was performed to analyse the genetic effect in exposed and non-exposed subjects. In all models an
140 additive genetic model was used. Gender, age and informative principal components for within-Europe
141 diversity were included as covariates. For the studies containing family data, a cluster variable
142 indicating the family relations was included.

143 We meta-analysed the results of the individual studies (discovery meta-analysis) and used two
144 selection procedures to identify SNPs that interact with ever active tobacco smoking in the adult onset
145 asthma. To assess heterogeneity Cochran's Q statistic was calculated of each SNP and a random
146 effect model was fitted.

147 Firstly, we followed the classical GWI study approach that is based on selection of the most significant
148 interaction effect, i.e. the overall difference between the genetic effect in smokers and non-smokers
149 with the lowest p-value. With this approach, smaller genetic effects occurring only after exposure to
150 active tobacco smoking can be missed. For that reason we also followed a second approach where
151 we selected genetic markers that are significantly associated with adult onset asthma in exposed
152 subjects, but not in non-exposed subjects.

153 In the first approach we meta-analysed the study specific interaction effects and we selected SNPs
154 with a fixed effect meta-analysis interaction effect with p-value $<10^{-4}$. In the second approach we
155 meta-analysed the genetic main effect in exposed and non-exposed subjects separately and we then
156 selected SNPs with a genetic effect with p-value $<10^{-4}$ only in exposed subjects based on the fixed
157 effect model. SNPs with the same effect in exposed and non-exposed subjects were omitted by
158 filtering on a nominal interaction effect (p-value $>10^{-2}$).

159 Only SNPs present in at least two studies were included in the discovery meta-analysis, yielding to a
160 total of 525,150 SNPs. Genome wide significance was set to a p-value $< 9.5*10^{-8}$ based on Bonferroni
161 correction. All SNPs selected from the discovery meta-analysis were tested for replication in an
162 independent population, the LifeLines Cohort Study [16] (Description of study in S1 File).

163 To investigate if the association between genetic background, tobacco smoking and adult onset
164 asthma was robust for the different smoking habits we assessed the genetic effects of the identified
165 SNPs on adult onset asthma in different strata of smoking habits (ever, current and former active

166 smoking, as well as current passive smoking) in the LifeLines cohort study: exposed versus non-
167 exposed to ever active tobacco smoking; exposed versus non-exposed to current active tobacco
168 smoking; exposed versus non-exposed to active smoking in the past; exposed versus non-exposed to
169 current passive smoking (details on the exposure definitions in S1 File). The analyses were conducted
170 using Plink 1.07 [17] and R [18]. For annotation and inspection of linkage disequilibrium (LD) patterns
171 WGAviewer [19] was used.
172

173 **Results**

174

175 The discovery genome-wide interaction meta-analysis consisted of 1,324 cases and 2,733 controls
176 derived from six studies (Table 1). Overall, active tobacco smoking was not associated with adult
177 onset asthma (Fig 2).

178 **Table 1. Study populations included in GWI study on active smoking and adult onset asthma**

Study	Country	Design	Ever tobacco smokers, % (N)	N	Cases			Controls		
					Total	Exposed	(%)	Total	Exposed	(%)
<i>Discovery study</i>										
B58C	UK	Cohort	27.2 (123)	452	232	63	27.2	220	60	27.3
ECRHS	European	Multicentre	57.4 (710)	1238	353	196	55.5	885	514	58.1
EGEA	France	Cohort, family structure	49.5 (407)	822	186	90	48.4	636	317	49.8
KSMU	Russia	Case-control	64.2 (255)	397	164	110	67.1	233	145	62.2
SAPALDIA	Switzerland	Cohort	55.9 (498)	891	354	201	56.8	537	297	55.3
TOMSK	Russia	Cohort, family structure	44.4 (114)	257	35	13	37.1	222	101	45.5
TOTAL			51.9 (2107)	4057	1324	673	48.7	2733	1434	49.7
<i>Replication study</i>										
LifeLines	Netherlands	Cohort	60.1% (7496)	12475	366	225	61.5	12109	7271	60.0

179 Numbers are shown for subjects who were successfully genotyped and whose genotypes passed all quality checks

180

181 **Fig 2. Forest plot for meta-analysis on the association between ever active tobacco smoking and adult onset asthma, without including the genetic**
 182 **effect.**

183 Firstly, we identified 50 SNPs in the discovery meta-analysis with an interaction p -value $< 10^{-4}$. None of
184 the SNPs reached genome-wide significance. The results for two SNPs showed heterogeneity across
185 studies (p -value Q -statistic < 0.05); these SNPs were omitted from further analysis. In the replication
186 study, 29 of the 48 SNPs were included since 19 SNPs were not successfully imputed in the LifeLines
187 Cohort Study or did not pass quality control (S1 Table). In total, 16 SNPs showed the same direction
188 of the interaction effect in the discovery and replication analysis. None of the associations reached
189 statistical significance in the replication study after Bonferroni correction for multiple testing for 29
190 SNPs (p -value < 0.0017) (Table 2). One SNP reached nominal significance: rs9969775 on
191 chromosome 9. For this SNP the interaction estimate in the discovery meta-analysis was $OR_{int} = 0.50$,
192 p -value $= 7.63 \times 10^{-5}$ and in the replication study: $OR_{int} = 0.65$, p -value $= 0.02$ (Table 2). Fig 3 shows the
193 forest plots with the results for the discovery studies. In the smoking stratified analysis, non-exposed
194 subjects carrying an A allele tended to have an increased asthma risk (discovery meta-analysis
195 $OR = 1.57$, p -value $= 1.88 \times 10^{-3}$, replication study $OR = 1.20$, p -value $= 0.19$), which was not observed in
196 exposed subjects.

Table 2. Top SNPs that interact with active tobacco smoking in adult onset asthma identified in first approach (overall interaction effect).[#]

Ch	SNP	Position	Effect allele	MAF*	Discovery meta-analysis						Replication study						Direction of the effect [¶]	
					Interaction			Exposed			Interaction			Exposed			Int	Exp
					OR _{int} [§]	95%CI	P [§]	OR [§]	95%CI	P [§]	OR _{int} [§]	95%CI	P [§]	OR [§]	95%CI	P [§]	D/R [¶]	D/R [¶]
1	rs4926457	245012644	C	0.42	0.65	0.52;0.80	4.49E-05	0.81	0.70;0.94	4.42E-03	1.03	0.76;1.39	0.86	1.06	0.88;1.28	0.54	-/+	-/+
1	rs10924824	244998447	G	0.42	0.64	0.52;0.79	2.96E-05	0.81	0.70;0.93	3.79E-03	0.99	0.74;1.34	0.97	1.05	0.87;1.27	0.61	-/-	-/+
1	rs4244627	245007487	G	0.42	0.64	0.52;0.79	3.52E-05	0.81	0.70;0.93	3.99E-03	1.02	0.75;1.38	0.91	1.05	0.87;1.27	0.62	-/+	-/+
1	rs10924823	244998415	T	0.42	0.65	0.52;0.80	4.28E-05	0.81	0.70;0.94	5.22E-03	0.99	0.73;1.34	0.96	1.05	0.87;1.27	0.62	-/-	-/+
2	rs1448187	111936830	T	0.28	0.65	0.53;0.81	9.34E-05	0.83	0.71;0.97	1.84E-02	1.04	0.75;1.45	0.81	1.06	0.87;1.31	0.55	-/+	-/+
2	rs2195614	221958757	A	0.43	1.51	1.23;1.85	8.10E-05	1.13	0.98;1.30	8.37E-02	1.04	0.77;1.41	0.80	1.04	0.86;1.25	0.70	+/+	+/+
2	rs2217431	221967489	A	0.43	1.53	1.24;1.88	5.14E-05	1.14	0.99;1.32	6.91E-02	1.04	0.77;1.41	0.80	1.04	0.86;1.25	0.70	+/+	+/+
2	rs13000320	237388433	C	0.17	0.57	0.44;0.76	9.00E-05	0.82	0.67;0.99	4.28E-02	0.86	0.58;1.28	0.46	0.92	0.72;1.19	0.55	-/-	-/-
3	rs428834	1629347	T	0.08	2.32	1.55;3.48	4.06E-05	1.57	1.22;2.03	5.68E-04	1.37	0.79;2.38	0.26	1.29	0.93;1.77	0.12	+/+	+/+
5	rs6863550	174552023	A	0.35	0.63	0.50;0.78	2.55E-05	0.75	0.64;0.87	1.89E-05	1.03	0.75;1.41	0.87	1.13	0.93;1.38	0.23	-/+	-/+

6	rs943801	165912238	C	0.21	0.59	0.46;0.77	6.69E-05	0.75	0.63;0.90	2.20E-03	1.00	0.70;1.42	0.99	1.13	0.91;1.41	0.27	-/0	-/+
6	rs2987296	165927063	T	0.14	0.52	0.38;0.71	3.35E-05	0.74	0.60;0.92	6.73E-03	1.14	0.76;1.70	0.53	1.12	0.87;1.43	0.37	-/+	-/+
6	rs643066	165872834	T	0.25	0.58	0.46;0.74	1.19E-05	0.79	0.67;0.94	6.77E-03	1.18	0.84;1.66	0.35	1.28	1.04;1.57	0.02	-/+	-/+
9	rs2988576	12352801	A	0.46	0.66	0.54;0.81	5.37E-05	0.75	0.65;0.87	1.13E-04	1.15	0.83;1.58	0.41	1.01	0.82;1.23	0.96	-/+	-/+
9	rs9969775	13561933	A	0.13	0.50	0.35;0.70	7.63E-05	0.84	0.65;1.07	1.50E-01	0.65	0.45;0.93	0.02	0.78	0.61;1.00	0.05	-/-	-/-
9	rs4338205	17736447	A	0.11	2.11	1.47;3.02	5.04E-05	1.46	1.16;1.84	1.18E-03	0.61	0.36;1.04	0.07	0.79	0.54;1.14	0.20	+/-	+/-
9	rs4745437	77497877	C	0.43	0.62	0.50;0.76	6.00E-06	0.82	0.71;0.95	7.69E-03	0.89	0.65;1.23	0.49	0.89	0.73;1.08	0.25	-/-	-/-
9	rs1328550	77499107	C	0.33	1.55	1.25;1.92	7.28E-05	1.21	1.05;1.41	1.04E-02	1.00	0.72;1.38	1.00	1.07	0.88;1.31	0.48	+/0	+/+
10	rs7074731	23142594	C	0.17	1.79	1.35;2.37	5.94E-05	1.32	1.10;1.59	2.93E-03	1.04	0.67;1.63	0.85	0.89	0.68;1.17	0.42	+/+	+/-
12	rs999481	5363096	G	0.42	0.66	0.53;0.81	8.26E-05	0.75	0.65;0.87	1.42E-04	0.75	0.55;1.03	0.07	0.85	0.70;1.04	0.11	-/-	-/-
12	rs1716466	118348243	G	0.41	1.52	1.24;1.87	6.66E-05	1.22	1.06;1.41	5.92E-03	0.96	0.70;1.30	0.77	1.08	0.89;1.31	0.44	+/-	+/+
12	rs7954580	128647904	A	0.14	0.55	0.41;0.74	9.99E-05	0.76	0.61;0.94	1.26E-03	0.94	0.61;1.46	0.79	0.90	0.69;1.19	0.46	-/-	-/-

							05		02										
13	rs9591994	58855563	C	0.33	0.64	0.52;0.80	8.09E-05	0.75	0.64;0.88	4.28E-04	0.76	0.39;1.49	0.42	1.01	0.64;1.59	0.96	-/-	-/+	
13	rs9544173	75597382	G	0.08	0.40	0.27;0.59	5.67E-06	0.73	0.55;0.97	2.97E-02	0.74	0.31;1.75	0.50	0.96	0.54;1.73	0.90	-/-	-/-	
16	rs8047401	79304514	T	0.35	0.66	0.53;0.81	9.98E-05	0.76	0.65;0.88	1.99E-04	0.88	0.62;1.25	0.47	0.87	0.71;1.08	0.22	-/-	-/-	
17	rs11077501	66037656	C	0.36	0.65	0.53;0.80	6.60E-05	0.83	0.71;0.96	1.33E-02	0.83	0.61;1.13	0.24	1.04	0.86;1.27	0.68	-/-	-/+	
20	rs1984399	40312545	A	0.42	1.59	1.29;1.96	1.31E-05	1.25	1.08;1.44	2.19E-03	0.68	0.50;0.93	0.02	0.89	0.73;1.09	0.26	+/-	+/-	
20	rs727336	40318090	T	0.42	1.55	1.26;1.91	3.58E-05	1.24	1.07;1.43	3.56E-03	0.65	0.48;0.88	0.01	0.88	0.72;1.07	0.21	+/-	+/-	
22	rs4553919	24941463	T	0.18	0.57	0.44;0.75	4.40E-05	0.80	0.66;0.98	2.71E-02	0.95	0.66;1.37	0.79	1.04	0.83;1.31	0.73	-/-	-/+	

198 # Selection based on interaction effect with active tobacco smoking. Additive genetic model. Interaction model included genetic effect, smoking effect, interaction effect, gender, age and informative
199 principal components. Ch: Chromosome; OR: Odds ratio; OR_{int}: Interaction Odds ratio; CI: Confidence interval; P: p-value

200 * MAF: Minor allele frequency (%), median of MAF in all discovery studies;

201 § OR and p-value are based on fixed effect model

202 ¶ Direction of the effect: + = positive, - = negative, 0 = no association, D/R: Discovery meta-analysis/Replication study

203

204 **Fig 3. Forest plots for the meta-analysis and replication study on the genetic effect of SNP rs9969775 on chromosome 9 in subjects exposed and**
205 **non-exposed to ever active tobacco smoking (identified in first approach).** The bottom forest plot presents the interaction meta-analysis and replication
206 study for this SNP. ORs are calculated using a fixed effect model.

207 Secondly, we identified 35 SNPs in the discovery meta-analysis with a genetic effect of $p\text{-value} < 10^{-4}$
208 and an interaction $p\text{-value} < 10^{-2}$. Findings did not reach genome-wide significance. None of the SNPs
209 showed heterogeneity across studies ($p\text{-value Q-statistic} < 0.05$). In the replication study, 27 of the 35
210 SNPs were included, since 8 SNPs were not successfully imputed in the LifeLines Cohort Study or did
211 not pass quality control (S1 Table). For 15 SNPs, the direction of the effect in the exposed subjects
212 was the same in the discovery and replication analysis. None of the associations reached statistical
213 significance in the replication study after Bonferroni correction for multiple testing for 27 SNPs ($p\text{-}$
214 $\text{value} < 0.0019$) (Table 3). One SNP reached nominal significance in the replication: rs5011804 on
215 chromosome 12 ($\text{OR}_{\text{int}} = 1.40$, $p\text{-value} = 0.03$). The interaction estimate for this SNP was $\text{OR}_{\text{int}} = 1.50$, $p\text{-}$
216 $\text{value} = 1.21 \times 10^{-4}$ in the discovery meta-analysis (Table 3). Fig 4 shows the forest plots with results for
217 the individual studies. In subjects who ever smoked, carriers of the minor allele C had an increased
218 risk for asthma (discovery meta-analysis $\text{OR} = 1.42$, $p\text{-value} = 1.56 \times 10^{-6}$; replication study $\text{OR} = 1.21$, $p\text{-}$
219 $\text{value} = 0.05$), while in non-exposed subjects, carriers of the C allele had no increased asthma risk
220 (discovery meta-analysis $\text{OR} = 0.92$, $p\text{-value} = 0.31$, replication study $\text{OR} = 0.86$, $p\text{-value} = 0.24$).
221 Four SNPs were identified by both approaches (Table 4), but the results for these SNPs could not be
222 replicated in LifeLines Cohort Study. The S2 Table shows the annotation of all SNPs identified in at
223 least one of the approaches.

Table 3. Top SNPs that interact with active tobacco smoking in adult onset asthma identified in second approach (genetic effect in exposed).#

Ch	SNP	Position	Effect allele	MAF*	Discovery meta-analysis						Replication study						Direction of the effect [¶]	
					Interaction			Exposed			Interaction			Exposed			Int	Exp
					OR _{int} [§]	95%CI	P [§]	OR [§]	95%CI	P [§]	OR _{int} [§]	95%CI	P [§]	OR [§]	95%CI	P [§]	D/R [¶]	D/R [¶]
1	rs7513225	20634784	A	0.38	0.72	0.58;0.89	1.88E-03	0.74	0.64;0.86	7.88E-05	0.98	0.68;1.42	0.93	1.15	0.92;1.45	0.23	-/-	-/+
3	rs9758775	163957528	C	0.27	0.52	0.34;0.79	2.14E-03	0.48	0.34;0.67	2.31E-05	1.45	1.01;2.08	0.04	1.06	0.86;1.31	0.57	-/+	-/+
5	rs3853475	141796799	C	0.38	1.43	1.16;1.76	7.88E-04	1.36	1.18;1.57	3.68E-05	1.26	0.93;1.72	0.14	1.06	0.88;1.28	0.56	+/+	+/+
6	rs1106841	43604640	C	0.38	1.44	1.16;1.77	7.36E-04	1.35	1.17;1.56	4.17E-05	0.94	0.69;1.28	0.70	1.05	0.87;1.28	0.58	+/-	+/+
6	rs2812719	80410202	A	0.41	1.38	1.12;1.69	2.03E-03	1.38	1.20;1.59	9.39E-06	1.08	0.79;1.47	0.63	1.12	0.93;1.36	0.23	+/+	+/+
6	rs723981	80421994	T	0.07	1.80	1.24;2.63	2.22E-03	1.77	1.37;2.27	9.74E-06	0.52	0.33;0.85	0.01	0.83	0.59;1.17	0.28	+/-	+/-
6	rs1883877	80439582	A	0.07	1.86	1.27;2.71	1.36E-03	1.77	1.37;2.27	9.74E-06	0.82	0.43;1.57	0.55	0.80	0.53;1.21	0.28	+/-	+/-
7	rs2015523	88616537	T	0.16	1.51	1.12;2.02	6.11E-03	1.52	1.23;1.86	7.31E-05	1.06	0.69;1.63	0.78	0.96	0.74;1.25	0.77	+/+	+/-
8	rs7816370	3037931	A	0.17	0.68	0.51;0.90	6.18E-03	0.66	0.54;0.79	1.51E-05	1.02	0.68;1.52	0.93	0.96	0.75;1.23	0.74	-/+	-/-
8	rs17601573	87135695	C	0.54	1.37	1.11;1.68	2.67E-03	1.36	1.18;1.56	2.04E-05	1.13	0.84;1.53	0.42	1.11	0.92;1.34	0.27	+/+	+/+

9	rs2890993	14741872	G	0.15	1.66	1.23;2.25	8.94E-03	1.52	1.25;1.85	3.76E-05	1.27	0.79;2.02	0.32	1.12	0.85;1.47	0.42	+/+	+/+
9	rs17061224	77273982	T	0.13	1.47	1.10;1.97	9.79E-03	1.49	1.23;1.82	6.47E-05	1.27	0.76;2.13	0.36	1.12	0.83;1.52	0.46	+/+	+/+
10	rs7906433	3878845	T	0.24	0.64	0.50;0.83	4.30E-04	0.70	0.60;0.83	3.91E-05	1.21	0.86;1.71	0.28	1.11	0.90;1.37	0.33	-/+	-/+
11	rs3818275	35265359	C	0.34	0.66	0.53;0.82	1.87E-04	0.74	0.63;0.86	7.11E-05	1.05	0.76;1.45	0.76	1.08	0.89;1.32	0.44	-/+	-/+
12	rs11047993	25439546	A	0.46	1.45	1.18;1.78	3.86E-04	1.41	1.22;1.63	2.52E-06	1.31	0.97;1.78	0.08	1.17	0.97;1.41	0.10	+/+	+/+
12	rs11047994	25439598	A	0.40	1.43	1.17;1.77	6.70E-04	1.35	1.16;1.55	5.34E-05	1.31	0.96;1.79	0.09	1.17	0.97;1.41	0.10	+/+	+/+
12	rs4578491	25440513	A	0.46	1.47	1.19;1.80	2.64E-04	1.43	1.24;1.65	1.34E-06	1.31	0.97;1.78	0.08	1.17	0.97;1.41	0.10	+/+	+/+
12	rs5011804	25441894	C	0.46	1.50	1.22;1.84	1.21E-04	1.42	1.23;1.65	1.56E-06	1.40	1.03;1.90	0.03	1.21	1.00;1.46	0.05	+/+	+/+
13	rs4884334	58839005	G	0.32	0.70	0.56;0.87	1.78E-03	0.72	0.61;0.85	9.66E-05	1.35	0.95;1.92	0.09	1.05	0.85;1.29	0.67	-/+	-/+
17	rs8071270	66907543	T	0.29	0.67	0.53;0.84	5.28E-04	0.73	0.62;0.85	8.68E-05	0.97	0.68;1.39	0.87	0.97	0.77;1.21	0.79	-/-	-/-
17	rs7226071	66917957	G	0.29	0.67	0.54;0.85	6.61E-04	0.73	0.62;0.85	9.76E-05	0.89	0.62;1.29	0.56	0.93	0.74;1.17	0.53	-/-	-/-
17	rs6501483	66920291	G	0.29	0.67	0.54;0.85	6.74E-04	0.73	0.62;0.85	8.58E-05	0.99	0.71;1.40	0.98	0.99	0.80;1.23	0.93	-/-	-/-

							04		05										
17	rs2367536	66975870	C	0.29	0.72	0.57;0.90	4.76E-03	0.72	0.62;0.85	6.83E-05	1.05	0.73;1.52	0.78	0.95	0.76;1.19	0.66	-/+	-/-	
18	rs724676	5916216	T	0.53	0.70	0.58;0.86	6.31E-04	0.76	0.66;0.87	9.28E-05	0.95	0.70;1.28	0.73	1.00	0.83;1.21	0.97	-/-	-/0	
19	rs618940	39328412	G	0.39	0.71	0.57;0.87	9.95E-04	0.74	0.64;0.85	2.93E-05	1.33	0.97;1.83	0.07	1.23	1.02;1.49	0.03	-/+	-/+	
20	rs6072658	40278039	C	0.19	0.61	0.47;0.78	1.51E-04	0.69	0.58;0.83	9.38E-05	1.61	1.10;2.35	0.01	1.20	0.96;1.49	0.11	-/+	-/+	
20	rs10485689	40312475	T	0.19	0.60	0.46;0.78	1.28E-04	0.68	0.56;0.82	4.23E-05	1.40	0.98;2.00	0.07	1.17	0.95;1.46	0.15	-/+	-/+	

225 # Selection based on genetic effect in subjects exposed to active tobacco smoking. Additive genetic model. Interaction model included genetic effect, smoking effect, interaction effect, gender, age
226 and informative principal components. Ch: Chromosome; Ref allele: Reference allele; OR: Odds ratio; OR_{int}: Interaction Odds ratio; CI: Confidence interval; P: p-value
227 * MAF: Minor allele frequency (%), median of MAF in all discovery studies;
228 § OR and p-value are based on fixed effect model
229 ¶ Direction of the effect: + = positive, - = negative, 0 = no association, D/R: Discovery meta-analysis/Replication study

230
231

232 **Fig 4. Forest plots for the meta-analysis and replication study on the genetic effect of SNP rs5011804 on chromosome 12 in subjects exposed and**
233 **non-exposed to ever active tobacco smoking (identified in second approach).** The bottom forest plot presents the interaction meta-analysis and
234 replication study for this SNP. ORs are calculated using a fixed effect model.

235
236

237 **Table 4. Top SNPs that interact with active tobacco smoking in adult onset asthma identified in both approaches.#**

Ch	SNP	Position	Effect allele	MAF*	Discovery meta-analysis						Replication study						Direction of the effect [¶]	
					Interaction			Exposed			Interaction			Exposed			Int	Exp
					OR _{int} [§]	95%CI	P [§]	OR [§]	95%CI	P [§]	OR _{int} [§]	95%CI	P [§]	OR [§]	95%CI	P [§]	D/R [¶]	D/R [¶]
5	rs4912832	141632275	A	0.46	1.59	1.30; 1.96	8.04E- 06	1.38	1.20;1.59	1.01E- 05	1.25	0.91;1.72	0.17	1.01	0.83;1.24	0.90	+/+	+/+
5	rs4541689	141631376	G	0.46	1.61	1.31;1.98	5.40E- 06	1.39	1.20;1.60	7.39E- 06	1.24	0.88;1.73	0.22	0.94	0.76;1.16	0.56	+/+	+/-
19	rs1759092	39368378	G	0.40	0.65	0.53;0.80	4.99E- 05	0.75	0.65;0.87	9.79E- 05	1.25	0.90;1.73	0.18	1.21	0.99;1.48	0.06	-/+	-/+
20	rs7262414	40245194	A	0.19	0.59	0.46;0.77	8.63E- 05	0.68	0.57;0.82	6.33E- 05	1.55	1.07;2.24	0.02	1.21	0.98;1.51	0.08	-/+	-/+

238 # Additive genetic model. Interaction model included genetic effect, smoking effect, interaction effect, gender, age and informative principal components.

239 Ch: Chromosome; Ref allele: Reference allele; OR: Odds ratio; OR_{int}: Interaction Odds ratio; CI: Confidence interval; P: p-value

240 * MAF: Minor allele frequency (%), median of MAF in all discovery studies;

241 [§]OR and p-value are based on fixed effect model

242 [¶]Direction of the effect: + = positive, - = negative, 0 = no association, D/R: Discovery meta-analysis/Replication study

243 The analyses of the robustness of the results showed that the identified SNPs interacted with active
 244 tobacco smoking and not with passive smoking (Table 5), effects being particularly apparent among
 245 ex-smokers.

246

247 **Table 5. Genetic effect of SNP rs5011804 following an additive model in the LifeLines cohort**
 248 **(N=12,475), stratified by different tobacco smoke exposures.**

Exposure	Stratum	N*	%	Genetic effect		
				OR	95% CI	p-value
Ever active tobacco smoking	Exposed	7496	60.1	1.21	1.00; 1.46	0.05
	Non-exposed	4979	39.9	0.86	0.68; 1.10	0.24
Current active tobacco smoking	Exposed	2800	22.5	0.84	0.61; 1.17	0.31
	Non-exposed	9666	77.5	1.14	0.97; 1.35	0.12
Ex smoker	Exposed	4624	37.1	1.44	1.14; 1.82	0.003
	Non-exposed	7842	62.9	0.89	0.73; 1.07	0.21
Current passive smoking	Exposed	2487	36.4	0.92	0.66; 1.27	0.61
	Non-exposed	4343	63.6	0.99	0.77; 1.28	0.96

249 * Numbers may not add up to 12,475, due to missing data on the specific exposure.

250

251 Discussion

252

253 This study is the first hypothesis-free genome-wide study specifically aiming to identify SNPs that
254 interact with active tobacco smoking with respect to asthma onset at adult age. The results are based
255 on data from GABRIEL, a large consortium on adult onset asthma. We found suggestive evidence for
256 an interaction between active tobacco smoking and rs9969775 on chromosome 9 and rs5011804 on
257 chromosome 12. Both SNPs are intergenic markers that do not annotate to genes nor do SNPs in LD
258 with these markers.

259

260 The SNPs found have not been identified previously in general GWA studies on asthma. Although the
261 identified markers do not annotate for a protein coding region, they may have a regulatory function.
262 rs9969775 is a tri-allelic polymorphism but in our datasets only two alleles were present (effect allele:
263 A, reference allele: C). Rs9969775 is located between the *FLJ41200* gene (distance ~ 129 KB, also
264 known as LINC01235) and *RP11-284P20.1* (distance ~ 366 KB). Both *FLJ41200* and *RP11-284P20.1*
265 are long intergenic non-protein coding RNA genes. With the development of whole genome and
266 transcriptome sequencing technologies, long noncoding RNAs have received increased attention.
267 Multiple studies indicate that they can regulate gene expression in many ways, including chromatin
268 modification, transcription and post-transcriptional processing [20]. A search for rs9969775 in the
269 ENCODE database (using the WashU Epi Genome Browser <http://epigenomegateway.wustl.edu/>)
270 showed that this SNP is located at a CpG site with a high methylation score in lung tissue. Further
271 analysis of this SNP using Haploreg indicated that this SNP is located in a region of active chromatin
272 in the lung, as indicated by a DNASE I hypersensitivity site, in an enhancer region (Haploreg version
273 4.1: <http://archive.broadinstitute.org/mammals/haploreg/haploreg.php>).

274 The second identified SNP, rs5011804, is located between the *KRAS* gene (distance ~ 38 KB) and the
275 *RPL39P27* gene (distance ~ 120 KB). The *KRAS* gene encodes a protein that is a member of the
276 small GTPase superfamily. Small GTPases regulate a wide variety of processes in the cell, including
277 growth, cellular differentiation, cell movement and lipid vesicle transport. *RPL39P27* is a ribosomal
278 protein pseudogene. Pseudogenes are fragments of genes that were functional but have been
279 silenced by one or more mutations[21]. It was assumed that pseudogenes were not functional but
280 recent studies suggest that they may have a functional role such as gene expression, gene regulation,

281 and generation of genetic diversity [22]. Finally, to gain more insight in the possible regulatory roles of
282 rs9969775 and rs5011804 on gene expression, data from the Genotype-Tissue Expression project
283 (<http://www.gtexportal.org/home/>) was used. The results showed that the SNPs were not associated
284 with gene expression of any gene in any tissue. In summary, our identified SNPs are located in
285 regions with potential regulatory function and future research is needed to unravel their role in adult
286 asthma further. Of interest, the two SNPs that were previously reported to be associated with adult
287 onset asthma [15] (rs17843604 and rs9273349 on chromosome 6) showed nominal significant
288 associations with asthma in both smokers and non-smokers but no interaction with active tobacco
289 smoking in our meta-analysis (S3 Table).

290

291 The GWI study design is specifically suited to identify novel SNPs that interact with an environmental
292 exposure in an unbiased way. Genes identified to interact with active tobacco smoking are crucial for
293 further insight in the etiology of adult onset asthma and development of effective strategies for asthma
294 prevention. A strength of our study is that we followed two different approaches to detect SNPs that
295 show a differential effect in subjects exposed and non-exposed to smoking. The classical GWI study
296 approach is to select SNPs with the largest interaction effect. Since we also aimed to identify
297 subpopulations that are genetically susceptible for active tobacco smoking we followed a second
298 approach in which we selected SNPs that only affected the risk of asthma in exposed subjects and not
299 in non-exposed subjects. In our analyses, four SNPs were identified with both approaches.

300

301 Since adult onset asthma is not common, only a subset of asthmatics is exposed, and the expected
302 effect size is small, a large sample size is needed to obtain a genome-wide significant finding. In this
303 study we combined data from multiple studies to achieve this. We additionally harmonized the
304 exposure and outcome definitions in the different studies as much as possible to improve the chance
305 of finding significant interactive effects. However, small differences in these definitions between
306 studies could create random error which compromises study power and thus makes it harder to detect
307 a significant interaction [23].

308

309 A limitation of our study is that active tobacco smoking is related to exposure to environmental smoke
310 at different periods in life, which makes it difficult to disentangle the effects of these exposures.

311 Therefore, we assessed the genetic effects of the identified SNPs on adult onset asthma in different
312 strata of smoking habits in the LifeLines Cohort Study. Results showed that genetic effects of the
313 identified SNPs were particularly apparent among ex smokers.

314

315 Two studies included in the meta-analysis contained cross-sectional and retrospectively collected
316 data. In these studies, asthma onset before the start of smoking could not be ruled out. Inclusion of
317 these subjects would lead to a dilution of the actual interaction between genetics and ever smoking on
318 adult onset asthma. Since data from the LifeLines Cohort Study showed that only eight (3.6%)
319 subjects out of 225 ever smoking adult onset asthmatics started smoking after the start of adult onset
320 asthma (data not shown), it is unlikely that this issue biased our results.

321

322 A general problem in GWI studies is their limited power, due to often a small number of subjects with
323 overlapping exposures and genotypes [24,25]. The power to detect an interaction can be increased by
324 assessing the association between exposure and genotype in a case-only design or a two-step design
325 [24,25] A case-only design assumes that exposure and genotype are independent. We chose not to
326 use this design given the known strong genetic component of smoking addiction, and relatively
327 modest violations of this assumption can have a substantial impact on bias relating to the interaction
328 parameters [26], hence leading to false positive or false negative findings [27]. In a two-step design
329 the interaction is tested among a selection of SNPs. The method we used to detect interactions
330 between exposure and genotype did not assume exposure and genotype independence nor did we a
331 priori select SNPs. To limit the possibility to miss possible interaction effects, we first selected the
332 most promising SNPs using an arbitrary threshold for interaction ($p < 10^{-4}$) and included them in a
333 replication study. A similar approach has been used successfully in a GWI study on interaction
334 between genetic markers and waist hip ratio on total serum cholesterol [28].

335

336 In summary, we performed two approaches for GWI analyses and identified SNPs on chromosome 9
337 and 12, both intergenic variants with potential regulatory functions. These are novel SNPs, previously
338 unidentified by regular genome-wide association and candidate gene studies that showed suggestive
339 evidence for interaction with active tobacco smoking in adult onset asthma. We propose that future
340 studies replicate our findings.

341

342 **References**

343

- 344 1. Scholtens S, Postma DS, Moffatt MF, Panasevich S, Granel R, Henderson AJ, et al. Novel
345 childhood asthma genes interact with in utero and early-life tobacco smoke exposure. *J Allergy Clin*
346 *Immunol.* 2014;133(3):885-888.
- 347 2. Burchfiel CM, Marcus EB, Curb JD, Maclean CJ, Vollmer WM, Johnson LR, et al. Effects of
348 smoking and smoking cessation on longitudinal decline in pulmonary function. *Am J Respir Crit Care*
349 *Med.* 1995;151(6):1778-1785.
- 350 3. Peat JK, Woolcock AJ, Cullen K. Decline of lung function and development of chronic airflow
351 limitation: A longitudinal study of non-smokers and smokers in busselton, western australia. *Thorax.*
352 1990;45(1):32-37.
- 353 4. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function
354 in adults with asthma. *N Engl J Med.* 1998;339(17):1194-1200.
- 355 5. Curjuric I, Zemp E, Dratva J, Ackerman-Liebrich U, Bridevaux PO, Bettschart RW, et al.
356 Determinants of change in airway reactivity over 11 years in the SAPALDIA population study. *Eur*
357 *Respir J.* 2011;37(3):492-500.
- 358 6. Siroux V, Pin I, Oryszczyn MP, Le Moual N, Kauffmann F. Relationships of active smoking to
359 asthma and asthma severity in the EGEA study. epidemiological study on the genetics and
360 environment of asthma. *Eur Respir J.* 2000;15(3):470-477.
- 361 7. Vogelberg C, Hirsch T, Radon K, Dressel H, Windstetter D, Weinmayr G, et al. Leisure time activity
362 and new onset of wheezing during adolescence. *Eur Respir J.* 2007;30(4):672-676.
- 363 8. Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness
364 from early childhood to age 33 in a national british cohort. *BMJ.* 1996;312(7040):1195-1199.
- 365 9. McWhorter WP, Polis MA, Kaslow RA. Occurrence, predictors, and consequences of adult asthma
366 in NHANES I and follow-up survey. *Am Rev Respir Dis.* 1989;139(3):721-724.
- 367 10. Vesterinen E, Kaprio J, Koskenvuo M. Prospective study of asthma in relation to smoking habits
368 among 14,729 adults. *Thorax.* 1988;43(7):534-539.
- 369 11. Oryszczyn MP, Annesi-Maesano I, Charpin D, Paty E, Maccario J, Kauffmann F. Relationships of
370 active and passive smoking to total IgE in adults of the epidemiological study of the genetics and

371 environment of asthma, bronchial hyperresponsiveness, and atopy (EGEA). *Am J Respir Crit Care*
372 *Med.* 2000;161(4 Pt 1):1241-1246.

373 12. Liu M, Rogers L, Cheng Q, Shao Y, Fernandez-Beros ME, Hirschhorn JN, et al. Genetic variants
374 of TSLP and asthma in an admixed urban population. *PLoS One.* 2011;6(9):e25099.

375 13. Berg ND, Husemoen LL, Thuesen BH, Hersoug LG, Elberling J, Thyssen JP, et al. Interaction
376 between filaggrin null mutations and tobacco smoking in relation to asthma. *J Allergy Clin Immunol.*
377 2012;129(2):374-80, 380.e1-2.

378 14. Curjuric I, Imboden M, Nadif R, Kumar A, Schindler C, Haun M, et al. Different genes interact with
379 particulate matter and tobacco smoke exposure in affecting lung function decline in the general
380 population. *PLoS One.* 2012;7(7):e40175.

381 15. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzignou E, Heath S, et al. A large-scale,
382 consortium-based genomewide association study of asthma. *N Engl J Med.* 2010;363(13):1211-1221.

383 16. Scholtens S, Smidt N, Swertz MA, Bakker SJ, Dotinga A, Vonk JM, et al. Cohort Profile: LifeLines,
384 a three-generation cohort study and biobank. *Int J Epidemiol.* 2015;44(4):1172-1180.

385 17. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: A tool set for
386 whole-genome association and population-based linkage analyses. *Am J Hum Genet.* 2007;81(3):559-
387 575.

388 18. R Development Core Team. R Foundation for Statistical Computing. R: A language and
389 environment for statistical computing. <http://www.R-project.org>. 2011.

390 19. Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, et al. WGAViewer: Software for genomic
391 annotation of whole genome association studies. *Genome Res.* 2008;18(4):640-643.

392 20. Shi X, Sun M, Liu H, Yao Y, Song Y. Long non-coding RNAs: a new frontier in the study of human
393 diseases. *Cancer Lett.* 2013;339(2):159-66.

394 21. Goodhead I, Darby AC. Taking the pseudo out of pseudogenes. *Curr Opin Microbiol.*
395 2014;23C:102-109.

396 22. Balakirev ES, Ayala FJ. Pseudogenes: are they "junk" or functional DNA? *Annu Rev Genet.*
397 2003;37:123-51.

398 23. Bookman EB, McAllister K, Gillanders E, Wanke K, Balshaw D, Rutter J, et al. Gene-environment
399 interplay in common complex diseases: Forging an integrative model-recommendations from an NIH
400 workshop. *Genet Epidemiol.* 2011;35(4):217-225.

- 401 24. Mukherjee B, Ahn J, Gruber SB, Chatterjee N. Testing gene-environment interaction in large-scale
402 case-control association studies: Possible choices and comparisons. *Am J Epidemiol.*
403 2012;175(3):177-190.
- 404 25. Ege MJ, Strachan DP, Cookson WO, Moffatt MF, Gut I, Lathrop M, et al. Gene-environment
405 interaction for childhood asthma and exposure to farming in central europe. *J Allergy Clin Immunol.*
406 2011;127(1):138-44, 144.e1-4.
- 407 26. Hunter DJ. Gene-environment interactions in human diseases. *Nat Rev Genet.* 2005;6(4):287-298.
- 408 27. Liu X, Fallin MD, Kao WH. Genetic dissection methods: Designs used for tests of gene-
409 environment interaction. *Curr Opin Genet Dev.* 2004;14(3):241-245.
- 410 28. Surakka I, Isaacs A, Karssen LC, Laurila PP, Middelberg RP, Tikkanen E, et al. A genome-wide
411 screen for interactions reveals a new locus on 4p15 modifying the effect of waist-to-hip ratio on total
412 cholesterol. *PLoS Genet.* 2011;7(10):e1002333.
- 413

414 **Supporting information**

415

416

417 **S1 File. Description of individual studies.**

418 **S1 Table. Complete results of all identified SNPs.**

419 **S2 Table. Annotation of the top SNPs identified in both approaches**

420 **S3 Table. Results for rs17843604 and rs9273349.**

421 **S1 Checklist. PRISMA 2009 Checklist**

422 **S2 Checklist. Meta-analysis on Genetic Association Studies Checklist | PLOS ONE**

Figures




Figure 1. Prisma flow diagram






Figure 2. Forest plot for meta-analysis on the association between ever active tobacco smoking and adult onset asthma, without including the genetic effect.

Exposed subjects



Non-exposed subjects



Interaction






Figure 3. Forest plots for the meta-analysis and replication study on the genetic effect of SNP rs9969775 on chromosome 9 in subjects exposed and non-exposed to ever active tobacco smoking (identified in first approach). The bottom forest plot presents the interaction meta-analysis and replication study for this SNP. ORs are calculated using a fixed effect model.

Exposed subjects



Non-exposed subjects



Interaction




Figure 4. Forest plots for the meta-analysis and replication study on the genetic effect of SNP rs5011804 on chromosome 12 in subjects exposed and non-exposed to ever active tobacco smoking (identified in second approach). The bottom forest plot presents the interaction meta-analysis and replication study for this SNP. ORs are calculated using a fixed effect model.